Eli Lilly and Company (NYSE:LLY) Stock Price Up 1.9% Following Earnings Beat

Posted by Geri Gentry on Aug 6th, 2026

Eli Lilly and Company logo Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) shot up 1.9% during mid-day trading on Thursday following a stronger than expected earnings report. The stock traded as high as $1,230.88 and last traded at $1,191.8720. Approximately 3,041,356 shares changed hands during trading, a decline of 3% from the average daily volume of 3,137,871 shares. The stock had previously closed at $1,169.86.

The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $2.22. The firm had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.69 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue was up 47.7% on a year-over-year basis. During the same period in the previous year, the business posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Strong Q2 results exceeded expectations. Revenue rose 48% year over year to approximately $23.0 billion, while non-GAAP EPS reached $8.38 versus the $6.16 consensus estimate. The results were driven primarily by volume growth for Mounjaro and Zepbound. Eli Lilly easily tops quarterly estimates and raises outlook
Positive Sentiment: Management raised its 2026 outlook again. Lilly now expects full-year revenue of $85 billion to $87 billion, up from $82 billion to $85 billion previously, and provided EPS guidance of $35.50 to $36.50. The higher forecast reflects sustained demand for diabetes and obesity treatments. Eli Lilly raises annual revenue forecast
Positive Sentiment: The weight-loss franchise continues to expand rapidly. Mounjaro sales increased 91%, while Mounjaro and Zepbound together generated nearly $15 billion in quarterly revenue and approximately two-thirds of total sales. Foundayo adoption is also gaining traction, with broader Medicare access supporting the addressable market. LLY Q2 earnings call raises outlook as Foundayo gains traction
Positive Sentiment: Pipeline and distribution developments add to the growth story. Lilly is advancing retatrutide toward a potential 2027 filing and expanding early access for certain patients. A new CVS weight-management partnership could improve GLP-1 distribution and patient access. Cantor Fitzgerald also raised its LLY price target to $1,410 and maintained an Overweight rating. Eli Lilly raises 2026 outlook again
Neutral Sentiment: Competitive sentiment has improved for Lilly. Novo Nordisk also beat estimates and raised guidance, but investors reacted more favorably to Lilly’s results, reinforcing perceptions that Lilly is widening its lead in the obesity-drug market. The divide between Eli Lilly and Novo Nordisk is widening
Negative Sentiment: Valuation and concentration remain risks. LLY trades at a high earnings multiple after a substantial rally, and much of its growth is concentrated in GLP-1 products. Manufacturing capacity, future competition, pricing pressure and the need to sustain exceptional demand could limit additional upside.
Neutral Sentiment: Amazon’s Medicare initiative may broaden access but increase competitive and pricing pressure. The program will offer Wegovy, Zepbound and Foundayo through Amazon Pharmacy for eligible patients, potentially supporting demand while intensifying price-based competition. Amazon is bringing the weight-loss drug race to Medicare

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on LLY shares. Jefferies Financial Group raised their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research note on Tuesday, June 9th. Leerink Partners boosted their target price on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Berenberg Bank upped their target price on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a report on Monday, June 22nd. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a research report on Tuesday, July 7th. Finally, UBS Group increased their price objective on Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,293.71.

Read Our Latest Analysis on LLY

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after purchasing an additional 1,006,885 shares during the last quarter. State Street Corp increased its position in shares of Eli Lilly and Company by 1.8% during the fourth quarter. State Street Corp now owns 35,361,916 shares of the company’s stock valued at $38,002,744,000 after purchasing an additional 635,358 shares during the period. Morgan Stanley raised its stake in shares of Eli Lilly and Company by 2.7% in the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock valued at $16,757,510,000 after buying an additional 407,166 shares in the last quarter. Capital World Investors raised its position in Eli Lilly and Company by 0.4% in the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock worth $16,154,619,000 after purchasing an additional 61,851 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Eli Lilly and Company by 10.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock worth $16,024,022,000 after buying an additional 1,432,069 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

The company has a market capitalization of $1.12 trillion, a P/E ratio of 42.34, a PEG ratio of 1.39 and a beta of 0.51. The stock has a fifty day simple moving average of $1,156.45 and a 200-day simple moving average of $1,045.49. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.